| Literature DB >> 33546176 |
Irene Rubia-Rodríguez1, Antonio Santana-Otero1, Simo Spassov2, Etelka Tombácz3, Christer Johansson4, Patricia De La Presa5,6, Francisco J Teran1,7, María Del Puerto Morales8, Sabino Veintemillas-Verdaguer8, Nguyen T K Thanh9,10, Maximilian O Besenhard11, Claire Wilhelm12, Florence Gazeau12, Quentin Harmer13, Eric Mayes13, Bella B Manshian14, Stefaan J Soenen14, Yuanyu Gu15, Ángel Millán15, Eleni K Efthimiadou16, Jeff Gaudet17, Patrick Goodwill17, James Mansfield17, Uwe Steinhoff18, James Wells18, Frank Wiekhorst18, Daniel Ortega1,19,20.
Abstract
The scientific community has made great efforts in advancing magnetic hyperthermia for the last two decades after going through a sizeable research lapse from its establishment. All the progress made in various topics ranging from nanoparticle synthesis to biocompatibilization and in vivo testing have been seeking to push the forefront towards some new clinical trials. As many, they did not go at the expected pace. Today, fruitful international cooperation and the wisdom gain after a careful analysis of the lessons learned from seminal clinical trials allow us to have a future with better guarantees for a more definitive takeoff of this genuine nanotherapy against cancer. Deliberately giving prominence to a number of critical aspects, this opinion review offers a blend of state-of-the-art hints and glimpses into the future of the therapy, considering the expected evolution of science and technology behind magnetic hyperthermia.Entities:
Keywords: cancer; hysteresis losses; magnetic hyperthermia; magnetic nanoparticles; magnetic particle imaging; nanoparticles synthesis; nanotoxicity; standardization; theranostics; thermometry
Year: 2021 PMID： 33546176 PMCID： PMC7913249 DOI： 10.3390/ma14040706
Source DB: PubMed Journal: Materials (Basel) ISSN： 1996-1944 Impact factor: 3.623